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httpcense.Abstract Purpose: Evaluation of the sensitivity and speciﬁcity of glypican3 (GPC3) in differenti-
ating hepatocellular carcinoma (HCC) from metastatic carcinomas of the liver in cell block material.
Patients and methods: Sixty cell blocks were prepared from liver FNAs performed in the radiodiag-
nosis department, National Cancer Institute, in the period between August 2011 and May 2012.
Cases diagnosed as hepatocellular carcinoma, or metastatic carcinoma were included in the study.
Cell block sections were stained with anti GPC-3. Sensitivity, speciﬁcity, and positive and negative
predictive values, of GPC3 were calculated. The ﬁnal diagnosis was based on the triple approach
of clinical data, radiological ﬁndings, as well as cytomorphologic features aided by GPC-3 results.
Results: 70% of cases were diagnosed as HCC, and 30% as metastatic carcinomas. 95.2% of HCC
cases expressed GPC3. Poorly differentiated cases showed the highest GPC3 sensitivity (100%), fol-
lowed by moderately differentiated cases (96.5%), while well differentiated cases expressed GPC3 in
90% of cases. 83.3% of metastatic carcinomas were negative for GPC3. In this study, sensitivity of
GPC-3 in HCC was 95.2%, speciﬁcity was 83.3%, positive and negative predictive values were 93%
and 88.2% respectively, and total accuracy was 91.7%.
Conclusion: Immunocytochemical staining for GPC3 in cell block material is a highly sensitive and
speciﬁc method capable of distinguishing HCC from the vast majority of metastatic carcinomas of
the liver.
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Hepatocellular carcinoma is the ﬁfth most common cancer and
the third most common cause of cancer-related death world-
wide [1]. Although the incidence of hepatocellular carcinoma
is lower in the developed Western world, the number of cases
is increasing [2]. In Egypt, Cancer PathologyRegistry (National
Cancer Institute, Cairo University, 2003–2004) reported thatational Cancer Institute, Cairo University.
.004
174 M. Zaakook et al.liver cancer formed 11.75% of malignancies of all digestive
organs and 1.68% of total malignancies. The included liver can-
cer cases were mostly hepatocellular carcinoma (70.48%), hepa-
toblastoma (10.24%), non-Hodgkin’s lymphoma (4.21%),
and adenocarcinoma unspeciﬁed (9.03%) [3].
The role of FNAC in the diagnosis of liver focal lesions is
well-established. Although 80% of malignant lesions of the li-
ver can be correctly diagnosed through cytomorphological
analysis and good clinico-radiologic correlation, around
20% can pose differential diagnostic problems. The distinc-
tion of moderately to poorly differentiated hepatocellular car-
cinoma from metastatic carcinoma may be a major problem
facing cytologists and this distinction is clinically important
[4].
Several immunohistochemical markers are available to as-
sist in this differential diagnosis, each with its strength and lim-
itations, making their judicious use imperative in biopsies with
limited material. The current available immunocytochemical
markers, such as alpha-fetoprotein, hepatocyte antigen (Hep-
Par 1), polyclonal carcinoembryonic antigen, CD10, and
CD34, have signiﬁcant diagnostic limitations [5].
Glypican-3 (GPC3) is one of the recent markers that had
been added to the hepatocellular phenotype listing [6]. GPC3
is a 60 kDa cell-surface protein, which is a member of the hep-
aran sulfate proteoglycan family (GPC1 to GPC6). It is an
oncofetal protein that is expressed in the embryo and is in-
volved in morphogenesis and growth control during develop-
ment [7]. The gene encoding GPC3 protein has been mapped
to Chromosome Xq26. Several studies have underlined an
important role of GPC3 in the regulation of cell growth, differ-
entiation, and migration [8].
Normally, GPC3 is expressed in fetal tissues and tropho-
blastic cells. Its expression is silenced in adult tissues [7], except
for normal ovarian, mammary, and mesothelial tissues [9].
Down regulation of GPC3 is frequently detected in ovarian
carcinoma, breast cancer, and mesothelioma [7], implying
GPC3 as a tumor suppressor gene in these organs. In contrast,
GPC3 may act as an oncofetal protein in carcinomas of vari-
ous other organs, such as hepatocellular carcinoma (HCC)
[10], ﬁbrolamellar HCC [11], germ cell tumors [12], broncho-
genic squamous cell carcinoma [13], and gastric cancer, as this
gene is highly expressed in tumor lesions compared with corre-
sponding normal tissues [14].
GPC3 was found to be expressed in the majority of cases of
HCC with a sensitivity ranging from 72% to 90% [15], and a
speciﬁcity between 96% and 100%. It has also been suggested
that poorly differentiated hepatocellular carcinomas are more
likely to express GPC-3 [16]. Its positivity is cytoplasmic, mem-
branous, and canalicular [6].
The current study aimed at assessing the role of glypican3
immunocytochemistry in differentiating hepatocellular carci-
noma from metastatic carcinoma of the liver, in terms of sen-
sitivity, speciﬁcity, positive and negative predictive values.
Patients and methods
The current study included 60 cases with malignant epithelial
liver tumors diagnosed by image-guided FNAC. The
fore-mentioned cases were selected from patients with hepatic
focal lesions referred to the radio-diagnosis department, and
registered at the cytopathology unit, pathology department,National Cancer Institute, Cairo University, during the period
from August 2011 to May 2012.
Eligibility criteria for inclusion in the study were as follows:
1. Malignant epithelial liver tumors, diagnosed as either
hepatocellular carcinoma or metastatic carcinoma.
2. Adequate cytological material for primary light micro-
scopic evaluation.
3. Availability of aspirate sufﬁcient for cell-block preparation.
Files of the patients were reviewed and relevant clinical and
radiological data were recorded. FNAC from liver focal
lesions was performed under ultrasonography or computerized
tomography guidance depending on size, site and number of
the focal lesions using a 23-gauge spinal needle. Six to eight
smear slides and one cell block were prepared for each case.
The slides were immediately ﬁxed in 95% ethyl alcohol for a
minimum of 15 min, and stained with modiﬁed Papanicolaou
stain. After careful screening of the slides prepared for each
case, malignant cases were selected, which were further classi-
ﬁed, if possible, into primary (HCC) or secondary (metastatic
carcinoma). Smears with inadequate cellularity or bad quality
were considered inadequate, and excluded from the study.
Cell blocks were made by allowing bloody material to clot,
whether on a slide or inside the syringe, scrapping the clotted
material into 10% neutral buffered formalin, and then process-
ing by routine histopathologic technique [17].
For each case, 5-lm section was cut and the slide was
stained with hematoxylin and eosin, all cell blocks were evalu-
ated for cellular adequacy. Additional section was prepared for
each case on an electrostatically charged glass slide, and
stained with monoclonal mouse, anti-glypican-3 antibody con-
centrate (Cell Marque, USA), clone 1G12. The labeled strepta-
vidin–biotin immunoperoxidase technique (LSAB) was used.
The reaction was detected using Diaminobenzidine (DAB),
with a hydrogen peroxide (H2O2) block. Positive control slides
were run with each staining set to ensure that all reagents were
working properly. Negative control slides, were performed by
substituting Phosphate Buffered Saline (PBS) for the primary
antibody, and were processed parallel with each staining set
to evaluate non-speciﬁc staining and better interpretation of
speciﬁc staining at the antigen site. All slides were counter-
stained with hematoxylin, and examined for GPC-3 expres-
sion. Glypican-3 staining intensity and pattern were graded
according to a 4-tier system as negative (grade 0), weak cyto-
plasmic staining (grade 1), moderate cytoplasmic staining
(grade 2), and strong cytoplasmic staining with membranous
accentuation (grade 3) [9].
For statistical analysis, data were coded and entered using
the statistics package SPSS version 15. Chi-square and Fish-
er-exact tests were used for testing proportion independence.
Validity of glypican-3 immunostaining in diagnosing hepato-
cellular carcinoma and differentiating it from metastatic carci-
noma, was done by calculating; sensitivity, speciﬁcity, positive
predictive value, negative predictive value, and total accuracy.
Results
The present study was conducted on 60 patients presented with
hepatic focal lesions, and diagnosed as malignant epithelial tu-
mors on the basis of ﬁne needle aspiration cytology. Cases
Figure 1 Well-differentiated hepatocellular carcinoma showing
monotonous population of small atypical hepatocytes in trabec-
ulae that are three cells thick or more (Papanicolaou ·400).
Figure 2 Well-differentiated HCC, in cell block preparations:
(A) cords of malignant hepatocytes, which exhibit well deﬁned cell
borders, ample granular cytoplasm, central round nucleus with
distinct nucleolus and granular chromatin (H&E ·400). (B) The
pseudoacinar pattern, with acinar-like structures lined by small
atypical hepatocytes, with intracytoplasmic greenish brown bile
pigment (green arrows) (H&E ·400).
GPC3 ICC in hepatocellular carcinoma 175were classiﬁed into hepatocellular carcinoma, and metastatic
carcinoma. HCC represented the majority of studied cases
42/60 (70%), with metastatic carcinomas constituting 18/60
(30%). The 18 cases of metastatic carcinomas were catego-
rized, on the basis of available previous clinical history, as
pancreatic adenocarcinoma 5/18 (27.8%), gastric adenocarci-
noma 1/18 (5.5%), non-small cell lung cancer 1/18 (5.5%),
chromophobe renal cell carcinoma 1/18 (5.5%), and colorectal
adenocarcinoma 2/18 (11%). Eight out of 18 cases (44.7%)
of metastatic carcinoma showed cytomorphologic features of
metastatic adenocarcinoma but had no settled diagnosis of
the primary tumor yet. These cases were categorized as
metastatic adenocarcinoma, not otherwise speciﬁed (NOS)
(Table 1).
Male predominance was observed in the studied cases in
both HCC and metastatic carcinoma with male to female ratio
of 9.5:1 and 1.25:1 respectively. The age range of the studied
cases was from 24 to 79 years, with a mean age of 62.5 years
in hepatocellular carcinoma with a standard deviation of
9.03, and 58.2 years in metastatic carcinoma group with a stan-
dard deviation of 11.52.
The majority of the studied cases of hepatocellular carci-
noma (71.4%) presented radiologically with multiple hepatic
focal lesions, and only 29.6% of cases were solitary. On the
other hand, metastatic carcinoma cases presented principally
by multiple hepatic focal lesions (72.2%).
The cytomorphologic analysis encompassed the study of cel-
lularity, pattern of arrangement, cytoplasmic and nuclear de-
tails and many additional features. The useful cytological
features in the diagnosis of HCC include trabecular pattern
with small capillaries transgressing or wrapping clusters of
tumor cells, hepatocytic cells with abundant eosinophilic gran-
ular cytoplasm, cytoplasmic bile pigment, intranuclear cyto-
plasmic inclusions, prominent nucleoli, and atypical stripped
nuclei. Based on the pattern of arrangement and nuclear fea-
tures, cases of HCC were classiﬁed into three groups: (i) well
differentiated, 10/42 cases (23.8%), (ii) moderately differenti-
ated, 29/42 cases (69%), and (iii) poorly differentiated, 3/42
cases (7.2%) (Figs. 1, 2 and 4–6 and Table 2).
In the current work, glypican-3 (GPC-3) staining intensity
and pattern were graded according to a 4-tier system as
(0, 1, 2, and 3) grades [9]. Glypican3 immunoreactivity was
cytoplasmic with sometimes membranous and occasionally
perinuclear accentuation. Forty out of 42 cases of HCC gave
positive immunocytochemical reaction to GPC3 (95.2%),
while only 3 out of 18 cases (16.7%) of metastatic carcinoma
showed positive reaction, with a P value <0.001 that is
statistically signiﬁcant (Table 3).
Two of 42 samples (4.8%) from the HCC group patients
were graded 0, and 40 of 42 (95.2%) samples were graded 1,Table 1 Different cytologic diagnoses of studied cases.
Cytologic diagnosis
HCC Metastatic carcinoma
Pancreatic
carcinoma
Gastric Non-small
cell lung
Chromophobe
renal cell
carcinoma
Colorectal carcinoma Metastatic adenocarcinoma NOS
No. of cases 42 5 1 1 1 2 8
Total 42 18
Figure 4 Moderately differentiated hepatocellular carcinoma,
showing malignant hepatocytes with abundant eosinophilic gran-
ular cytoplasm, coarse granular chromatin, prominent nucleoli,
and sinusoidal endothelial cells (red arrow) (Papanicolaou ·1000).
Figure 5 Moderately differentiated HCC, showing pleomorphic
atypical hepatocytes with numerous naked nuclei having the same
features as cells in the trabeculae (Papanicolaou ·400).
Figure 6 Poorly differentiated HCC, showing pleomorphic
tumor giant cells with bizarre nuclei. Although, it still shows
focal hepatocellular differentiation; prominent nucleoli and intra-
nuclear inclusions (arrow) (Papanicolaou ·400).
Figure 3 Well differentiated HCC showing weak cytoplasmic
staining for GPC-3 (grade1) (GPC3 ·400).
Table 2 Different grades of differentiation among the studied
cases of hepatocellular carcinoma.
Grade of diﬀerentiation Hepatocellular carcinoma
No. Percent
Well-diﬀerentiated 10 23.8
Moderately-diﬀerentiated 29 69
Poorly-diﬀerentiated 3 7.2
Total 42 100
176 M. Zaakook et al.2 or 3; 1 case was graded 1 (2.4%), 22 cases were graded 2
(55%), and 17 cases were graded 3 (42.5%) (Figs. 3 and
7–9). Among the patients of the metastatic carcinoma group,
15/18 (83.3%) samples were graded 0, and 3/18 (16.7%)
samples were graded 2 (Figs. 10–13). P value was calculated
to be <0.001 that is statistically signiﬁcant (Table 4).
GPC-3 was found to be expressed in the majority of cases
of HCC with a sensitivity (95.2%), speciﬁcity (83.3%), positive
predictive value (PPV) (93%), negative predictive value (NPV)
(88.2%) and total accuracy of 91.7%.
Discussion
Hepatocellular carcinoma is one of the most common cancers
in the world, with an estimated incidence of 1,000,000 cases per
year [18]. Recent reports demonstrate that the incidence of
HCC has increased sharply in the last 5–10 years [19], with
an especially high incidence in Egypt [20].
Metastatic tumors account for most hepatic malignant
diseases in non-cirrhotic livers in developed Western countries.
In the cirrhotic liver, however, primary hepatic malignant
tumors are more common than are metastatic tumors [21].
The distinction of hepatocellular carcinoma from other
neoplasms involving the liver can be difﬁcult and is especially
challenging in core and ﬁne-needle aspiration biopsies.
Preliminary studies have demonstrated the promise of
GPC3 immunohistochemistry for the diagnosis of hepatocellu-
lar carcinoma. It has also been suggested that poorly differen-
tiated hepatocellular carcinomas are more likely to express
GPC3 [16]. It may be very helpful in differentiating HCC from
benign hepatic lesions and from metastatic neoplasms of the li-
ver [22].
Figure 9 Two cases of moderately differentiated hepatocellular
carcinoma showing strong cytoplasmic staining for GPC-3 with
membranous accentuation (grade 3) (GPC-3 ·400).
Table 3 Glypican-3 immunostaining results among studied cases.
Glypican-3 immunostaining Hepatocellular carcinoma Metastatic carcinoma
No. Percent No. Percent
Positive 40 95.2 3 16.7
Negative 2 4.8 15 83.3
Total 42 100 18 100
Figure 7 Moderately differentiated HCC showing negative
staining for GPC3 (grade 0) (GPC3 ·400).
Figure 8 Moderately differentiated HCC showing moderate
cytoplasmic staining for GPC-3 (grade 2) (GPC3 ·400).
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diagnosed on the basis of ﬁne needle aspiration cytology. The
ﬁnal diagnosis for each case was achieved on the basis of the
triple approach of: (1) radiological ﬁndings, (2) clinical data
including tumor marker serum level (alpha-fetoprotein and
others related to primary tumors elsewhere), and a history of
any primary carcinoma that could metastasize to the liver, as
well as (3) cytomorphologic criteria aided by the GPC-3 immu-
nocytochemical result.
In the current work, 42 out of 60 cases (70%) of liver focal
lesions were diagnosed as HCC, representing the majority of
our studied cases, with metastatic carcinomas constituting 18
out of 60 cases (30%). This ﬁnding agrees with what Ligato
et al. (2008) have recorded that 58.5% of malignant hepatic tu-
mors were HCC (representing the majority of cases) and
41.5% were metastatic in origin [22].
The 18 cases of metastatic carcinomas were categorized as
5/18; pancreatic adenocarcinoma (27.8%), 1/18; gastric cancer(5.5%), 1/18; non-small cell lung cancer (5.5%), 1/18; chromo-
phobe renal cell carcinoma (5.5%), 2/18; colorectal cancer
(11%), and 8/18; metastatic adenocarcinoma, not otherwise
speciﬁed (NOS) (44.7%). In metastatic cases, speciﬁcation of
the primary site was based on clinical history. Cases diagnosed
as metastatic adenocarcinoma (NOS) have no settled diagnosis
of primary tumor elsewhere. These results agree with what was
reported in a previous study concerning liver metastasis that
lung, colon, pancreas, breast, and stomach are the most fre-
quent primary sites of origin for metastatic carcinoma of liver,
representing 24.8%, 15.7%, 10.9%, 10%, and 6.1% of cases,
respectively [23]. However, the higher percentages of these pri-
mary sites in the mentioned study than the current study (with
the exception of pancreatic adenocarcinoma) could be attrib-
uted to the dependence of most clinicians in a large number
of patients presenting with focal liver lesions and with a known
previous history of primary cancer elsewhere on correlation of
radiological data, clinical history and tumor marker serum
level without necessitating tissue diagnosis for managing
these cases as metastatic. Another explanation is the higher
presentation of cases of metastatic adenocarcinoma (NOS)
over other categories of metastatic carcinoma in the current
work.
Figure 11 Negative glypican-3 immunostaining of metastatic
adenocarcinoma (grade 0) (GPC-3 ·400).
Figure 12 Cell block preparation of metastatic chromophobe
renal cell carcinoma showing sheets of polygonal cells, with well-
deﬁned cell borders, and dense granular cytoplasm (H&E ·400).
Figure 13 Glypican-3 immunostaining of metastatic chromo-
phobe renal cell carcinoma, showing moderate cytoplasmic
staining for GPC-3 (grade 2) (GPC-3 ·400).
Figure 10 Fine needle aspiration of metastatic adenocarcinoma
in both direct smear (upper) (Papanicolaou stain ·400), and cell
block (lower) (H&E ·400).
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rhotic livers (83.5%), than in non-cirrhotic livers (16.5%). This
agrees with what is reported in the literature of the higher fre-
quency of hepatocellular carcinoma cases (58%) in cirrhotic
livers [24].
The majority of the studied cases of hepatocellular carci-
noma (71.4%) presented radiologically with multiple hepatic
focal lesions, and only 29.6% of cases were in the form of sol-
itary hepatic focal lesions. The multicentric form of hepatocel-
lular carcinoma was also reported by Craig [25], to represent
the majority of hepatocellular carcinoma cases. On the con-
trary, Ahuja et al. (2007) reported that most of hepatocellular
carcinoma cases (68%) presented as solitary hepatic focal le-
sions [25,4]. This discrepancy could be attributed to variations
between different countries in the main implicated carcino-
genic agents that give different HCC radiological presenta-
tions. On the other hand, metastatic carcinoma cases
presented principally by multiple hepatic focal lesions
(72.2%), and this agrees with Ahuja et al. (2007) who observed
that 68% of metastatic carcinoma cases presented by multiple
hepatic focal lesions [4].
Cytomorphologically, according to the pattern of arrange-
ment and nuclear features, the studied cases of HCC were clas-
siﬁed into three groups: (i) well differentiated, 10/42 cases
(23.8%), (ii) moderately differentiated, 29/42 cases (69%),
and (iii) poorly differentiated, 3/42 cases (7.2%).
After careful cytomorphologic examination of cases a pro-
visional diagnosis was given in each case, GPC3 immunocyto-
chemistry was carried out to complete the diagnostic picture.
In the current work, two of 42 samples (4.8%) from the
HCC group were graded 0, and 40 of 42 samples (95.2%) were
graded 1, 2 or 3; 1 case was graded 1 (2.4%), 22 cases were
graded 2 (52.4%), and 17 cases were graded 3 (40.5%). These
ﬁndings are slightly higher than what have been reported by
Kandil and Cooper (2007), and Ligato et al. (2008) ; 90%
and 83.3 of HCC cases showed positive immunoreactivity for
glypican-3, respectively [9,22].
In contrast, among the patients of metastatic carcinoma
group, 15/18 (83.3%) samples were graded 0, and 3/18
(16.7%) samples were graded 2. Our ﬁndings were slightly
higher than what is reported in the literature regarding GPC-
3 positivity in metastatic carcinoma cases that ranged from
0% to 5.9% [9,22,26].
Table 4 Glypican-3 staining intensity grades among the studied cases.
Glypican-3 immunostaining intensity Hepatocellular carcinoma Metastatic carcinoma
No. Percent No. Percent
Grade 0 2 4.8 15 83.3
Grade 1 1 2.4 0 0
Grade 2 22 52.4 3 16.7
Grade 3 17 40.5 0 0
Total 42 100 18 100
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astatic carcinoma group include: (1) metastatic chromophobe
renal cell carcinoma, which showed diffuse moderately-intense
staining (Figs. 12 and 13). This unexpected result matched with
what was published by Okon´ (2008); where glypican-3 immuno-
histochemistry was performed on 625 cases of renal cell carci-
noma, revealing strong positive staining in 15 cases, moderate
in 4 and weak in 68. The reactivity was particularly evident in
chromophobe renal cell carcinoma (32/40) [27], (2) metastatic
pancreatic adenocarcinoma, which showed focalmoderately-in-
tense positive staining. This ﬁnding was also reported by Yan et
al. (2011); the primary adenocarcinomas of the pancreas (1/17;
6%) have displayed focal glypican-3 immunoreactivity [28],
and (3) metastatic colorectal adenocarcinoma, which showed
focal moderately-intense positive staining. This ﬁnding was also
reported by Yamauchi et al. (2005) who achieved similar results
where one case of colorectal carcinoma exhibited focal positivity
for GPC-3 [26].
In our study, GPC-3 was found to be expressed in the
majority of cases of HCC with a sensitivity (95.2%), speciﬁcity
(83.3%), positive predictive value (PPV) (93%), negative pre-
dictive value (NPV) (88.2%) and total accuracy of 91.7%.
Other studies showed sensitivity ranging from 72% to 90%,
speciﬁcity between 96% and 100%, positive predictive value
of 95%, and negative predictive value of 85.7% [15,16,22].
It has to be noted that there is some risk of sampling prob-
lems and consequently, negative results do not always exclude
the diagnosis of HCC. On the other hand, we should be cau-
tious to interpret a positive immunostaining for GPC3 as a
deﬁnitive proof for a diagnosis of HCC. This is because of
the reported focal expression of GPC3 in dysplastic nodules,
and in rare cases of metastatic carcinomas to the liver [22].
Therefore, it is mandatory to interpret a positive immunostain-
ing result for GPC3 within the appropriate clinical, radiologi-
cal, and cytomorphologic context.
Finally, we conclude that immunocytochemical staining for
GPC3 using FNA cell block material is a highly sensitive and
speciﬁc method capable of distinguishing HCC from the vast
majority of metastatic carcinomas of the liver.
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